Loading...
XASE
VNRX
Market cap70mUSD
Jul 17, Last price  
0.68USD
1D
-3.39%
1Q
38.02%
Jan 2017
-85.20%
IPO
-83.09%
Name

VolitionRX Ltd

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
57.01
EPS
—
Div Yield, %
—
Shrs. gr., 5y
17.17%
Rev. gr., 5y
135.32%
Revenues
1m
+59.10%
000000054,968014,785000017,09613,43390,035306,392775,3021,233,511
Net income
-27m
L-23.65%
-13,105-36,987-26,295-21,803-15,816-10,947-2,608,463-4,083,050-3,710,289-8,213,529-9,530,242-11,905,278-14,769,207-18,008,623-16,028,670-20,481,914-26,970,468-30,268,793-35,319,078-26,967,836
CFO
-26m
L+43.35%
35-49,999-17,31139,946-5,750-4,650-1,686,065-2,314,582-3,084,206-4,140,825-8,766,323-9,055,693-12,193,238-14,733,027-12,739,455-16,464,244-20,853,919-15,277,742-18,062,999-25,893,624
Earnings
Aug 12, 2025

Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
URL
https://volition.com/
IPO date
Feb 06, 2015
Employees
111
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,234
59.10%
775
153.04%
306
240.30%
Cost of revenue
28,258
36,471
32,926
Unusual Expense (Income)
NOPBT
(27,025)
(35,696)
(32,620)
NOPBT Margin
Operating Taxes
(330)
Tax Rate
NOPAT
(27,025)
(35,696)
(32,290)
Net income
(26,968)
-23.65%
(35,319)
16.68%
(30,269)
12.23%
Dividends
Dividend yield
Proceeds from repurchase of equity
8,592
28,356
6,556
BB yield
-16.55%
-55.52%
-4.87%
Debt
Debt current
1,129
1,703
1,358
Long-term debt
1,747
5,429
4,743
Deferred revenue
Other long-term liabilities
26,977
423
420
Net debt
(389)
(13,598)
(4,766)
Cash flow
Cash from operating activities
(25,894)
(18,063)
(15,278)
CAPEX
(277)
(1,084)
(1,570)
Cash from investing activities
(574)
(1,084)
(1,570)
Cash from financing activities
8,657
28,983
6,938
FCF
(31,656)
(31,332)
(29,152)
Balance
Cash
3,264
20,730
10,867
Long term investments
Excess cash
3,203
20,691
10,852
Stockholders' equity
(230,359)
(203,161)
(167,524)
Invested Capital
233,096
200,977
169,791
ROIC
ROCE
1,634.58%
EV
Common stock shares outstanding
86,531
71,235
55,350
Price
0.60
-16.32%
0.72
-70.49%
2.43
-22.61%
Market cap
51,919
1.65%
51,075
-62.03%
134,501
-18.65%
EV
50,329
36,567
129,183
EBITDA
(25,686)
(34,282)
(31,430)
EV/EBITDA
Interest
340
222
173
Interest/NOPBT